- Home
- NSTS vs BLRX Comparison
NSTS vs BLRX Comparison
Compare NSTS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | BLRX |
|---|---|---|
| Founded | 1921 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 12.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NSTS | BLRX |
|---|---|---|
| Price | $12.10 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 8.3K | ★ 23.2K |
| Earning Date | 11-13-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,762,000.00 | ★ $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $2.30 |
| 52 Week High | $13.32 | $14.70 |
Technical Indicators
Market Signals| Indicator | NSTS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.80 | 39.47 |
| Support Level | $11.70 | $2.85 |
| Resistance Level | $12.52 | $3.10 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 56.71 | 13.80 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.